Business
Beyond Air® Schedules Second Fiscal Quarter 2022 Financial Results Conference Call and Webcast
Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time GARDEN CITY, N.Y., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a
About this update from Beyond Air, Inc.
[{"type":"text","content":"Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time\nGARDEN CITY, N.Y., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that it will report financial results for its second fiscal quarter ended September 30, 2021 on Thursday, November 11, 2021. The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day. Conference Call & WebcastThursday, November 11th @ 4:30 PM ETDomestic:877-407-0784International:201-689-8560Passcode:13722892Webcast:http://public.viavid.com/index.php?id=146470 About Beyond Air, Inc.Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit® can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit® for clinical trials for the treatment of severe lung infections such as acute viral pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net. Forward Looking StatementsThis press release contains “forward-looking statements” concerning inhaled nitric-oxide and the Company’s LungFit®† product, including statements with regard to potential regulatory developments, the potential impact on patients and anticipated benefits associated wit...